Compare BCBP & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BCBP | STTK |
|---|---|---|
| Founded | 2000 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 139.0M | 275.9M |
| IPO Year | N/A | 2020 |
| Metric | BCBP | STTK |
|---|---|---|
| Price | $7.89 | $4.18 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $9.25 | $4.00 |
| AVG Volume (30 Days) | 87.1K | ★ 887.9K |
| Earning Date | 01-30-2026 | 11-06-2025 |
| Dividend Yield | ★ 8.14% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $64,592,000.00 | $1,000,000.00 |
| Revenue This Year | $23.06 | N/A |
| Revenue Next Year | $3.55 | N/A |
| P/E Ratio | $157.92 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.41 | $0.69 |
| 52 Week High | $12.26 | $4.89 |
| Indicator | BCBP | STTK |
|---|---|---|
| Relative Strength Index (RSI) | 45.71 | 56.01 |
| Support Level | $7.54 | $4.10 |
| Resistance Level | $8.02 | $4.65 |
| Average True Range (ATR) | 0.18 | 0.41 |
| MACD | -0.01 | -0.07 |
| Stochastic Oscillator | 53.03 | 42.56 |
BCB Bancorp Inc is a bank holding company. The company offers loans, including commercial and multi-family real estate loans, home equity loans, construction loans, consumer loans, and commercial business loans; FDIC-insured deposit products, such as savings and club accounts, interest and non-interest bearing demand accounts, money market accounts, certificates of deposit and individual retirement accounts, and retail and commercial banking services, including wire transfers, money orders, safe deposit boxes, a night depository, debit cards, online banking, gift cards, fraud detection and automated teller services.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.